You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF
Epidemiology
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

 

Online download statistics by month:

Online download statistics by month: June 2021 to March 2024

AbstractFullPdf
Jun 2021496149612400
Jul 2021555255531482
Aug 2021248624871022
Sep 202120312031952
Oct 2021150815091501
Nov 202111311130739
Dec 2021820831450
Jan 2022881944485
Feb 2022773749500
Mar 2022798786448
Apr 2022895888381
May 2022758774396
Jun 2022523490240
Jul 2022481473195
Aug 2022450408195
Sep 2022427440192
Oct 2022377359155
Nov 2022357345150
Dec 2022323307156
Jan 2023350325134
Feb 2023337308143
Mar 2023326290128
Apr 20236725625
May 20238013721
Jun 20235423414
Jul 2023629328
Aug 20236685320
Sep 20237295921
Oct 202310826327
Nov 202313256322
Dec 20238265922
Jan 20246396027
Feb 20245893714
Mar 20245306830
Total355772700912695